Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab.

Iris Lin Richard MelsheimerRachel H BhakPatrick LefebvreMaral DerSarkissianBruno EmondAngela LaxCatherine NguyenMelody WuYinong Young-Xu

Published in: Current medical research and opinion (2022)

Patients switching from innovator to biosimilar IFX were more likely to discontinue treatment and switch to another innovator biologic (notably back to innovator IFX) than those remaining on innovator IFX; however, reasons for discontinuation and switching are unknown.

Keyphrases

end stage renal disease
rheumatoid arthritis
ejection fraction
prognostic factors
smoking cessation